| Pacritinib vs best available therapy, including ruxolitinib, in patients with myelofibrosis: a randomized clinical trial J Mascarenhas, R Hoffman, M Talpaz, AT Gerds, B Stein, V Gupta, ... JAMA oncology 4 (5), 652-659, 2018 | 339 | 2018 |
| Myelodysplastic syndromes, version 2.2017, NCCN clinical practice guidelines in oncology PL Greenberg, RM Stone, A Al-Kali, SK Barta, R Bejar, JM Bennett, ... Journal of the National Comprehensive Cancer Network 15 (1), 60-87, 2017 | 330 | 2017 |
| Targeting megakaryocytic-induced fibrosis in myeloproliferative neoplasms by AURKA inhibition Q Jeremy Wen, Q Yang, B Goldenson, S Malinge, T Lasho, RK Schneider, ... Nature medicine 21 (12), 1473-1480, 2015 | 154 | 2015 |
| NCCN guidelines insights: myeloproliferative neoplasms, version 2.2018 RA Mesa, C Jamieson, R Bhatia, MW Deininger, CD Fletcher, AT Gerds, ... Journal of the National Comprehensive Cancer Network 15 (10), 1193-1207, 2017 | 145 | 2017 |
| Disruption of the ASXL1 gene is frequent in primary, post-essential thrombocytosis and post-polycythemia vera myelofibrosis, but not essential thrombocytosis or polycythemia … BL Stein, DM Williams, C O’Keefe, O Rogers, RG Ingersoll, JL Spivak, ... Haematologica 96 (10), 1462, 2011 | 127 | 2011 |
| Sex differences in the JAK2V617F allele burden in chronic myeloproliferative disorders BL Stein, DM Williams, NY Wang, O Rogers, MA Isaacs, N Pemmaraju, ... Haematologica 95 (7), 1090, 2010 | 94 | 2010 |
| Age-related differences in disease characteristics and clinical outcomes in polycythemia vera BL Stein, S Saraf, U Sobol, A Halpern, J Shammo, D Rondelli, L Michaelis, ... Leukemia & lymphoma 54 (9), 1989-1995, 2013 | 90 | 2013 |
| Polycythemia Vera: An Appraisal of the Biology and Management 10 Years After the Discovery of JAK2 V617F BL Stein, ST Oh, D Berenzon, GS Hobbs, M Kremyanskaya, RK Rampal, ... Journal of Clinical Oncology 33 (33), 3953-3960, 2015 | 86 | 2015 |
| AKT is a therapeutic target in myeloproliferative neoplasms I Khan, Z Huang, Q Wen, MJ Stankiewicz, L Gilles, B Goldenson, ... Leukemia 27 (9), 1882-1890, 2013 | 86 | 2013 |
| Downregulation of GATA1 drives impaired hematopoiesis in primary myelofibrosis L Gilles, AD Arslan, C Marinaccio, QJ Wen, P Arya, M McNulty, Q Yang, ... The Journal of clinical investigation 127 (4), 1316-1320, 2017 | 81 | 2017 |
| Central role of ULK1 in type I interferon signaling D Saleiro, S Mehrotra, B Kroczynska, EM Beauchamp, P Lisowski, ... Cell reports 11 (4), 605-617, 2015 | 80 | 2015 |
| Myeloproliferative neoplasms, version 2.2017, NCCN clinical practice guidelines in oncology R Mesa, C Jamieson, R Bhatia, MW Deininger, AT Gerds, I Gojo, J Gotlib, ... Journal of the National Comprehensive Cancer Network 14 (12), 1572-1611, 2016 | 71 | 2016 |
| Mutations in MPNs: prognostic implications, window to biology, and impact on treatment decisions JM Shammo, BL Stein Hematology 2014, the American Society of Hematology Education Program Book …, 2016 | 63 | 2016 |
| Thrombotic and bleeding complications in classical myeloproliferative neoplasms B McMahon, BL Stein Seminars in thrombosis and hemostasis 39 (01), 101-111, 2013 | 63 | 2013 |
| Gender and Vascular Complications in the JAK2 V617F‐Positive Myeloproliferative Neoplasms BL Stein, A Rademaker, JL Spivak, AR Moliterno Thrombosis 2011 (1), 874146, 2011 | 63 | 2011 |
| Biological rationale and clinical use of interferon in the classical BCR-ABL-negative myeloproliferative neoplasms BL Stein, RV Tiu Journal of Interferon & Cytokine Research 33 (4), 145-153, 2013 | 58 | 2013 |
| A phase I, open-label, dose-escalation, multicenter study of the JAK2 inhibitor NS-018 in patients with myelofibrosis S Verstovsek, M Talpaz, E Ritchie, M Wadleigh, O Odenike, C Jamieson, ... Leukemia 31 (2), 393-402, 2017 | 57 | 2017 |
| Polycythemia vera disease burden: contributing factors, impact on quality of life, and emerging treatment options BL Stein, AR Moliterno, RV Tiu Annals of hematology 93, 1965-1976, 2014 | 56 | 2014 |
| Treatment options for patients with chronic myeloid leukemia who are resistant to or unable to tolerate imatinib B Stein, BD Smith Clinical therapeutics 32 (5), 804-820, 2010 | 48 | 2010 |
| Myelodysplastic syndromes, version 2.2015 PL Greenberg, RM Stone, R Bejar, JM Bennett, CD Bloomfield, U Borate, ... Journal of the National Comprehensive Cancer Network 13 (3), 261-272, 2015 | 47 | 2015 |
